Please assess the completion status of the following clinical trial:

Trial Title: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Is at least 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place)~2. Has pathologically confirmed NSCLC that is Stage IIIB, metastatic (Stage IVA or IVB), or recurrent, and which is not amenable to curative intent therapy.~3. Tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity-ex19del or L858R-either alone or in combination with other EGFR mutations (eg, G719X, exon 20 insertions, S7681, L861Q)~4. Has Eastern Cooperative Oncology group performance status of 0, 1, or 2 at the time of enrollment.~5. Has adequate organ function at the time of enrollment.~6. Has QTc interval of ≤ 470 ms~7. Male participants must agree to use a highly effective method of contraception and to refrain from donating sperm while receiving study treatment~8. Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies: is not of childbearing potential OR is of childbearing potential and using a highly effective contraceptive method while receiving study treatment AND agrees not to donate eggs (ova, oocytes) during this period~9. All female participants must have a negative serum or urine pregnancy test result within 48 hours prior to initiation of study drug dosing~Exclusion Criteria:~1. Is a candidate for curative intent therapy for the NSCLC diagnosis.~2. Tumor has mixed small-cell and non-small-cell pathology.~3. Has received prior systemic treatment for metastatic NSCLC. Prior chemotherapy or immunotherapy is permitted, provided that it was used for treatment of locoregional NSCLC as a component of curative intent therapy and administration was completed more than 6 months ago.~4. Has refractory nausea and vomiting, chronic gastrointestinal disease(s), inability to swallow the formulated product (percutaneous endoscopic gastrostomy tube administration may be allowed if tablets are not crushed), or a history of previous significant bowel resection-any of which would preclude adequate absorption of aumolertinib or osimertinib.~5. Has active or past medical history of interstitial lung disease, drug-induced interstitial lung disease or radiation pneumonitis that required steroid treatment~6. Has evidence of active bacterial, viral, or fungal infection which would preclude safe enrollment, as assessed by the treating Investigator.~7. Has significant concomitant condition, that in the Investigator's judgment would prevent the participant from receiving study treatment or being followed in this study, or which otherwise renders the participant inappropriate for the study.~8. For participants in the aumolertinib monotherapy and aumolertinib with chemotherapy arms, use of strong CYP3A4 inhibitors/inducers within 14 days before initial study drug dosing and use of grapefruit-containing products within 72 hours before initial study drug dosing is prohibited.~9. Has a history of prolonged QT syndrome or Torsades de Pointes~10. Has any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, including evidence of QT prolongation (QTc \>470 ms for males and \>480 ms for females) or has any factor, including any current medication(s), known to increase the risk of QTc prolongation or the risk of arrhythmic events~11. Hypersensitivity or allergy to aumolertinib or osimertinib or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aumolertinib monotherapy (Type: EXPERIMENTAL): None
- Aumolertinib + platinum-based doublet chemotherapy (Type: EXPERIMENTAL): For adenocarcinoma, either:~* Aumolertinib + cisplatin with pemetrexed, or~* Aumolertinib + carboplatin with pemetrexed~For squamous cell carcinoma, one of the following:~* Aumolertinib + cisplatin or carboplatin with paclitaxel;~* Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or~* Aumolertinib + cisplatin or carboplatin with gemcitabine
- Osimertinib monotherapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy